Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2021 | KEYNOTE-407: 3-year follow-up of pembrolizumab plus chemo in NSCLC

Andrew Robinson, MD, MSc, FRCPC, Queen’s University, Kingston, ON, shares an update on the three-year follow-up data from the randomized Phase III KEYNOTE-407 study (NCT02775435), investigating pembrolizumab plus chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC). At a median follow-up of 40.1 months, the median overall survival (OS) for patients receiving pembrolizumab plus chemotherapy was 17.2 months and the median progression-free survival (PFS) was 13.8 months, versus a median OS of 11.6 months and a median PFS of 9.1 months for patients receiving placebo plus chemotherapy. Overall the study found that pembrolizumab plus chemotherapy demonstrated durable benefits compared to chemotherapy alone, without additional toxicity. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.